Advanced Filters
noise

Bone Neoplasm Clinical Trials

A listing of Bone Neoplasm medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 119 clinical trials

Single Arm Phase II Study of Fractionated Stereotatic Radiation Therapy (FSRT) for Bone Metastases in Breast Cancer

Fractionated stereotatic radiation therapy (FSRT) that very precisely delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. The purpose of this study is to find out if FSRT is safe and effective in the treatment of metastatic …

- 100 years of age Both Phase 1/2

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

This phase II trial studies how well dexrazoxane hydrochloride works in preventing heart-related side effects of chemotherapy in participants with blood cancers, such as acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia, and myeloproliferative neoplasms. Chemoprotective drugs, such as dexrazoxane hydrochloride, may protect the heart from the side effects of …

12 - 100 years of age Both Phase 2

Efficacy and Safety of Apalutamide in Combination With 89Sr as Neoadjuvant Therapy in Prostate Cancer With ≤10 Bone Metastases

The aim of this study is to evaluate the efficacy and safety of apalutamide in combination with 89Sr as neoadjuvant therapy in prostate cancer with ≤10 bone metastases. The primary endpoint is PFS and the second endpoints are pCR, rPFS, PSA response, pain score, number and extent of bone metastases.

18 - 100 years of age Male Phase N/A

Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.

Non-randomized, open, two-cohort, phase II, multicenter national clinical trial. 20 sites in Spain. Cohort 1 includes soft-tissue sarcoma and osteosarcoma (21 patients), while Cohort 2 includes chordoma patients only (19 patients). Palbociclib will be administered orally at a dose of 125 mg once a day for 21 consecutive days followed …

18 - 80 years of age Both Phase 2
C Caterina Vacchi-Suzzi, PhD

Definitive Radiation for High-Risk Spine Metastases

This study is looking at whether patients with cancer that has aggressively spread to the spine can be treated with stereotactic body radiation therapy only and avoid a large spine surgery

18 - 100 years of age Both Phase 2
K Katarzyna Maleszewska

Regorafenib in Patients With Refractory Primary Bone Tumors

The aim of the project is to improve treatment outcomes in patients with primary malignant bone tumors, refractory to standard therapy, by increasing the availability of advanced therapy, as well as to develop treatment options using advanced molecular diagnostics for patients who have not responded to the standard therapeutic regimen, …

9 - 21 years of age Both Phase 1/2
T Theo Foukakis, MD, PhD

Use of GnRHa During Chemotherapy for Fertility Protection

Many cytotoxic drugs may harm the fertility of young women treated for cancer. The aim of the study is to investigate if the Gonadotropin-Releasing Hormone agonist (GnRHa) during cancer treatment can preserve the fertility of young female cancer subjects. Approximately 300 women with newly diagnosed breast cancer and up to …

14 - 42 years of age Female Phase 3
Y Yingqi Hua, PhD

Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma

This study will evaluate the safety and efficacy of NK510 in the treatment of Osteosarcoma and Soft Tissue Sarcoma.NK510 will be administered by intravenous injection. The safety and efficacy of this treatment will be evaluated.

10 - 75 years of age Both Phase N/A
W Wei Guo, MD

ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas

HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. This is a phase 2, open-label, multi-center study to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of HS-20093 as a monotherapy in patients with relapsed or refractory …

18 - 100 years of age Both Phase 2

Bone-sparing Chemoradiotherapy for Anal Cancer - DACG-II

This study proposal includes a prospective clinical trial of bone sparing treatment planning in anal cancer patients. We seek to lower the risk of bone damage, while adhering with the constrains to the bowel, bladder and other conventional Organs At Risk, and finally to describe the fraction of pelvic insufficiency …

18 - 100 years of age Both Phase N/A

Rewrite in simple language using AI